Almonertinib plus anlotinib for first-line advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be removed by surgery or treated with radiation and chemotherapy together.
- Your cancer cells have both an EGFR mutation and a TP53 mutation (special gene changes).
- You have not had chemotherapy or radiation for advanced cancer, or if you did, it was more than 6 months ago.
- You are between 18 and 75 years old, and your general health is good enough for daily activities (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
- Your blood counts and organ function (liver, kidneys) are within acceptable ranges, and you do not have serious heart problems, active infections, or bleeding risks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TQB2928 combined with a common targeted therapy (a third-generation EGFR TKI) for people with advanced non-small cell lung cancer. The goal is to see if this combination is safe and effective, especially for those whose cancer has progressed after previous treatment.
This trial tests a combination of two drugs, Almonertinib and Lastet, for people with a specific type of advanced lung cancer (EGFR-positive NSCLC) that cannot be removed by surgery or cured with radiation and chemotherapy. The goal is to see if the combination works better than standard treatments.
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
This trial tests combining a targeted pill (almonertinib) with precise radiation to the lung for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the pill alone.
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
This Phase 2 study tests two targeted medicines together (aumolertinib plus anlotinib) as first treatment for advanced lung cancer with specific gene changes (EGFR 19del or L858R plus TP53). It aims to see whether the combination is effective and safe when starting treatment.
Hear when a new Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.